Patheon to build pharmaceutical development center in Bourgoin, France
RESEARCH TRIANGLE PARK, NC,
"We currently provide our customers with solid dose Phase 3 and commercial supply from our facilities in
The state-of-the-art facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes up to 120 kg. It will consist of a new pilot plant and equipment designed to contain high potency products. Process trains will be scalable to commercial lines, offering clients the ability to produce Phase 3 and commercial product in the same location.
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.
Patheon, with an integrated development and manufacturing network of 11 facilities and eight development centers across
%SEDAR: 00001700EFor further information: Wes Wheeler, President and Chief Executive Officer, Tel: (919) 226-3200, Email: email@example.com; Eric Evans, Chief Financial Officer, Tel: (919) 226-3204, Email: firstname.lastname@example.org; Wendy Wilson, Investor Relations, Tel: (919) 226-3313, Email: email@example.com